CompletedPhase 1NCT03206021

COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

Studying Ependymoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: The Hospital for Sick Children
Principal Investigator: Vijay Ramaswamy, MD PhD FRCPC
The Hospital for Sick Children
Intervention: 5 Azacytidine(drug)
Enrollment: 31 target
Eligibility: 1-18 years · All sexes
Timeline: 2017 – 2024

Study locations (17)

Children's National Medical Center, Washington D.C., District of Columbia, United States
Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia
Women's and Children's Hospital, Adelaide, Australia
Monash Children's Hospital, Clayton, Australia
John Hunter Children's Hospital, Lambton, Australia
Perth Children's Hospital, Perth, Australia
Queensland Children's Hospital, South Brisbane, Australia
Sydney Children's Hospital, Sydney, Australia
Children's Hospital at Westmead, Westmead, Australia
Alberta Children's Hospital, Calgary, Alberta, Canada
BC Children's Hospital, Vancouver, British Columbia, Canada
McMaster Children's Hospital, Hamilton, Ontario, Canada
London Health Sciences Centre, London, Ontario, Canada
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Hospital for Sick Children, Toronto, Ontario, Canada
+2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03206021 on ClinicalTrials.gov

Other trials for Ependymoma

Additional recruiting or active studies for the same condition.

See all trials for Ependymoma →

← Back to all trials